Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730950 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT01730950 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 182 participants.
The verdict
NCT01730950, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma
Interventions
- RADIATION radiation therapy
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2012-12-20 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730950
The ClinicalTrials.gov registry entry for NCT01730950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT01730950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730950 about?
NCT01730950 is a clinical study titled "Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma". This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others...
What is the current status of trial NCT01730950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2012-12-20. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT01730950?
The interventions under investigation include: radiation therapy (RADIATION), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01730950?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.